首页>投融资
Day One Biopharmaceuticals
上市后再融资
Day One Biopharmaceuticals, Inc.于2018年11月在特拉华州注册成立，名称为Hero Therapeutics Holding Company，LLC。随后，公司于2018年12月更名为Day One Therapeutics Holding Company，LLC，并于2020年3月更名为Day One Biopharmaceuticals Holding Company，LLC。该公司有两家子公司：Day One Biopharmaceuticals，Inc.（以前称为Hero Therapeutics Inc.）于2018年11月在特拉华州注册成立的全资子公司，以及于2019年12月在特拉华州注册成立的多数子公司DOT Therapeutics-1，Inc.。他们是临床阶段的生物制药公司，致力于开发和商业化针对患者的靶向疗法具有基因定义的癌症的所有年龄段。该公司的主要候选产品DAY101是一种口服，脑渗透性高选择性II型pan-RAF激酶抑制剂。
基本信息
-
公司全称Day One Biopharmaceuticals Inc
-
类型癌症药物开发商
-
产业领域药品研发/制造、医药研发/制造、生物药、化学药
-
公司人数101~500人
-
地址2000 Sierra Point Parkway Suite 501 Brisbane CA 94005
-
联系电话1-650-4840899
-
邮箱info@dayonebio.com
-
成立时间2018-01-01
投融资
-
2024-08-01上市后再融资1.75亿美元Access IndustriesFrazier ManagementWellington ManagementDeerfieldBraidwellFairmount
-
2023-06-09增发1.5亿美元未透露
-
2021-05-27上市1.49亿美元未透露
-
2021-02-10B轮1.3亿美元RA CapitalAtlas VentureAccess IndustriesCanaan PartnersViking Global InvestorsT. Rowe PricePerceptive AdvisorsJanus Henderson InvestorsFranklin Templeton InvestmentsBVF PartnersBoxer Capital
-
2020-05-22A轮6000万美元Atlas Venture
- 加载更多
相关投融资企业
收并购
Advanced Accelerator Applications (AAA), a subsidiary of Novartis AG, founded in 2002 by Italian academics as a spin-off from the European Organization for Nuclear Research (CERN, Switzerland), develops diagnostic and therapeutic products, including PET radiopharmaceuticals. The company focuses on Personalized Medicine, aimed at providing treatments tailored to a patient's profile and disease, using predictive, preventive and personalized procedures. In January 2018, AAA became a subsidiary of Novartis AG.In July 2016, the company opened its first US manufacturing facility in Millburn, NJ. The Millburn plant served as a distribution center for NETSPOT.In April 2014, AAA opened a new office in the US located at Manhattan, NY. At that time, the company planned to set up a new manufacturing facility in the US.In February 2012, AAA planned to build a radiopharmaceutical facility in Murcia, Spain. The facility was expected to be completed within 18 months.By December 201
B轮
Veradermics Inc (美国)：Veradermics是一家位于美国的生物技术公司，专注于皮肤健康和美容产品的研发。公司的主要研究领域包括皮肤再生、抗衰老和皮肤修复。Veradermics利用其专有的生物材料和技术平台，开发了一系列高效的皮肤护理产品。公司的产品线包括抗衰老面霜、皮肤修复凝胶和皮肤再生面膜等。
B轮
Qnovia, formerly known as Respira Technologies, is focused on developing inhaled drug delivery platforms to deliver drugs for nicotine replacement therapy and cardiopulmonary diseases.In September 2022, the company changed its name from Respira Technologies to Qnovia.In September 2022, the company raised USD 17M in Series A funding led by Blue Ledge Capital, DG Ventures, Evolution VC Partners, Gaingels, TL Capital, and Vice Ventures,
浙公网安备33011002015279
本网站未发布麻醉药品、精神药品、医疗用毒性药品、放射性药品、戒毒药品和医疗机构制剂的产品信息